NeuroEM — Fighting Alzheimer’s

Pioneering transcranial electromagnetic treatment against Alzheimer’s Disease

The Problem

Alzheimer’s Disease (AD) is a degenerative condition that affects millions of Americans — yet, there is no therapy to reverse, stabilize, or even slow down the progressive cognitive decline associated to the disease. AD causes dysfunction and loss of brain cells leading to memory loss and other cognitive impairments.

What the Company Does

NeuroEM Therapeutics is a clinical-stage medical device company developing an easy-to-wear head device called the MemorEM, made to effectively treat and prevent Alzheimer’s Disease. During daily 1-hour treatments in-home, as administered by the patient’s caregiver, the electromagnetic waves penetrate the skull to go deep into the brain to break-up the two toxic proteins currently thought to the be root cause of Alzheimer’s Disease. The MemorEM affects AD markers in both blood and cerebrospinal fluid (CSF), and has even been demonstrated to enhance brain function (as shown by MRI). This is a first-in-class solution; no other therapy in clinical development has this ability. Multiple publications highlighting the technology and clinical value can be found on NeuroEM’s website.

Market

An estimated 6 million Americans suffer from Alzheimer’s disease and another 5 million from Mild Cognitive Impairment (MCI), often referred to as a prelude to Alzheimer’s onset. Alzheimer’s costs the U.S. almost $300 billion per year. Various competitors are testing near infrared (LED) waves to treat Alzheimer’s Disease (e.g., Vielight), however, NeuroEM’s unique technology is proven to penetrate the human skull and has shown a reversal of AD cognitive impairment.

Founding Team

Dr. Gary Arendash, Ph.D. (UCSF Medical School, UCLA Brain Research Institute) has 30 years’ research experience and over 100 peer-reviewed articles in top journals including the Journal of Alzheimer’s Disease. Dr. Arendash founded NeuroEM in 2013 to continue development of TEMT against Alzheimer’s Disease. Five years of pre-clinical research conducted by him and his colleagues at the University of South Florida resulted in 5 peer-reviewed publications.

What They Need Help With

In addition to forming partnerships, NeuroEM is looking to hire a part-time Chief Medical Officer or Chief Clinical Trials Officer to lead up their clinical efforts. NeuroEM has also just started a $500,000 seed raise. Feel free to reach out directly or to contact us for further information. Connect with the NeuroEM team.

Subscribe To The Buzz To Get More Startups In Your Inbox